BILE ACIDS IN LIVER AND GASTROINTESTINAL CANCER.

Bile acids (BAs) are cholesterol-derived metabolites synthesized by hepatocytes and secreted in bile to follow an inter-organ transit to the intestine, where they facilitate fat digestion and the absorption of lipids and liposoluble vitamins. Traditionally considered mere end products of cholesterol catabolism, they are now acknowledged to play intricate roles in regulating intermediary metabolism by controlling the expression of crucial genes. Additionally, they exert a significant impact on inflammation, cytotoxicity, and carcinogenesis. Moreover, BAs have a critical impact on the crosstalk between gut microbiota and host physiology, which affects the progression of liver and gastrointestinal cancers. Clinical data and results from studies of animal models support the involvement of BAs in the development of hepatocellular carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, and pancreatic cancer. On the other hand, BAs and their derivatives have been proposed as pharmacological tools in strategies to restore abnormal hepatobiliary function and target cytostatic agents to cancers of the enterohepatic circuit. In the present review, we summarize basic concepts of BA physiology and regulation, as well as new advances in this expanding field of renewed interest for cancer biology, lending further support for the key role of BAs in liver and gastrointestinal cancer.

• Publication year

  2025

• Venue

  Seminars in Cancer Biology

• Publication date

  2025-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.semcancer.2025.09.002PMID 40935218
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.

  2025cited by this paper
• Liver specific transgenic expression of CYP7B1 attenuates early western diet-induced MASLD progression

  2025cited by this paper
• Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis

  2025cited by this paper
• Bile acid synthesis impedes tumor-specific T cell responses during liver cancer.

  2025cited by this paper
• A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid

  2025cited by this paper
• Cholesterol’s new tricks propel MASH-HCC: impact in immunotherapy

  2024cited by this paper
• How bile acids and the microbiota interact to shape host immunity

  2024cited by this paper
• Post‐diagnosis dietary factors, supplement use and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis

  2024cited by this paper
• Post‐diagnosis physical activity and sedentary behaviour and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis

  2024cited by this paper
• Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma

  2024cited by this paper
• The role of metabolic reprogramming in kidney cancer

  2024cited by this paper
• Bile Acids in Pancreatic Carcinogenesis

  2024cited by this paper
• Lithocholic acid phenocopies anti-ageing effects of calorie restriction

  2024cited by this paper
• High-fat/high-sucrose diet results in a high rate of MASH with HCC in a mouse model of human-like bile acid composition

  2024cited by this paper
• Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.

  2024cited by this paper
• The bile acid profile.

  2024cited by this paper
• Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis

  2024cited by this paper
• Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress.

  2024cited by this paper
• Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data

  2024cited by this paper
• The Role of Bile Acids in Pancreatic Cancer.

  2024cited by this paper
• The role of bile acid receptor TGR5 in regulating inflammatory signalling

  2024cited by this paper
• Another renaissance for bile acid gastrointestinal microbiology

  2024cited by this paper
• Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2024cited by this paper
• Bile acid metabolism and signaling in liver disease.

  2024cited by this paper
• Diet changes due to urbanization in South Africa are linked to microbiome and metabolome signatures of Westernization and colorectal cancer

  2024cited by this paper
• Ursodeoxycholic Acid Platinum(IV) Conjugates as Antiproliferative and Antimetastatic Agents: Remodel the Tumor Microenvironment through Suppressing JAK2/STAT3 Signaling.

  2024cited by this paper
• CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage

  2023cited by this paper
• Farnesoid X receptor activation inhibits pancreatic carcinogenesis.

  2023cited by this paper
• Plasma Bile Acid Profiling and Modulation of Secreted Mucin 5AC in Cholangiocarcinoma

  2023cited by this paper
• Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions

  2023cited by this paper
• The microbial-derived bile acid lithocholate and its epimers inhibit Clostridioides difficile growth and pathogenicity while sparing members of the gut microbiota

  2023cited by this paper
• Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets

  2023cited by this paper
• Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemia.

  2023cited by this paper
• TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs

  2023cited by this paper
• Synthesis and biological evaluation of cholic acid-conjugated oxaliplatin as a new prodrug for liver cancer.

  2023cited by this paper
• Bile acids as drivers and biomarkers of hepatocellular carcinoma

  2022cited by this paper
• Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment

  2022cited by this paper
• Etiopathogenesis and pathophysiology of cholestasis

  2022cited by this paper
• Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.

  2022cited by this paper
• Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation

  2022cited by this paper
• Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review)

  2022cited by this paper
• Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention

  2021cited by this paper
• Regulation of Intestinal Barrier Function by Microbial Metabolites

  2021cited by this paper
• Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.

  2021cited by this paper
• MDM2 Binding Protein Induces the Resistance of Hepatocellular Carcinoma Cells to Molecular Targeting Agents via Enhancing the Transcription Factor Activity of the Pregnane X Receptor

  2021cited by this paper
• Association between Pre-Diagnostic Serum Bile Acids and Hepatocellular Carcinoma: The Singapore Chinese Health Study

  2021cited by this paper
• Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.

  2021cited by this paper
• Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma

  2021cited by this paper
• STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.

  2021cited by this paper
• The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer

  2021cited by this paper
• Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma

  2021cited by this paper
• Altered bile acid glycine : taurine ratio in the progression of chronic liver disease

  2021cited by this paper
• Dominant Bacterial Phyla from the Human Gut Show Widespread Ability To Transform and Conjugate Bile Acids

  2021cited by this paper
• Manipulating Liver Bile Acid Signaling by Nanodelivery of Bile Acid Receptor Modulators for Liver Cancer Immunotherapy.

  2021cited by this paper
• β-Cyclodextrin-cholic acid-hyaluronic acid polymer coated Fe3O4-graphene oxide nanohybrids as local chemo-photothermal synergistic agents for enhanced liver tumor therapy.

  2020cited by this paper
• Regulation and modulation of antitumor immunity in pancreatic cancer

  2020cited by this paper
• Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B‐related hepatocellular carcinoma

  2020cited by this paper
• The gut-liver axis in liver disease: pathophysiological basis for therapy.

  2020cited by this paper
• Dietary fat, bile acid metabolism and colorectal cancer.

  2020cited by this paper
• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

  2020cited by this paper
• Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study

  2020cited by this paper
• Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

  2020cited by this paper
• Bile accelerates carcinogenic processes in pancreatic ductal adenocarcinoma cells through the overexpression of MUC4

  2020cited by this paper
• Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells

  2020cited by this paper
• Molecular Physiology of Bile Acid Signaling in Health, Disease and Aging.

  2020cited by this paper
• Synthesis of New Cisplatin Derivatives from Bile Acids

  2020cited by this paper
• Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma.

  2020cited by this paper
• Global chemical effects of the microbiome include new bile-acid conjugations

  2020cited by this paper
• Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma

  2020cited by this paper
• Vancomycin prevents fermentable fiber-induced liver cancer in mice with dysbiotic gut microbiota

  2020cited by this paper
• Vitamin D Receptor Activation in Liver Macrophages Ameliorates Hepatic Inflammation, Steatosis, and Insulin Resistance in Mice

  2020cited by this paper
• Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition[S]

  2019cited by this paper
• Endoplasmic Reticulum Stress-induced Upregulation of STARD1 Promotes Acetaminophen-induced Acute Liver Failure.

  2019cited by this paper
• Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis

  2019cited by this paper
• Models for Understanding Resistance to Chemotherapy in Liver Cancer

  2019cited by this paper
• Bile Acids as Metabolic Regulators and Nutrient Sensors.

  2019cited by this paper
• Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.

  2019cited by this paper
• Tauroursodeoxycholate—Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives

  2019cited by this paper
• The acidic pathway of bile acid synthesis: Not just an alternative pathway

  2019cited by this paper
• UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.

  2019cited by this paper
• Discovery of glycocholic acid and taurochenodeoxycholic acid as phenotypic biomarkers in cholangiocarcinoma

  2018cited by this paper
• Therapeutic developments in pancreatic cancer: current and future perspectives

  2018cited by this paper
• Bile acids and their respective conjugates elicit different responses in neonatal cardiomyocytes: role of Gi protein, muscarinic receptors and TGR5

  2018cited by this paper
• The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

  2018cited by this paper
• Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model

  2018cited by this paper
• Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease

  2018cited by this paper
• Vitamin D receptor gene methylation in hepatocellular carcinoma.

  2018cited by this paper
• Hepatocellular carcinoma

  2018cited by this paper
• Comparison of the effects of sodium phenobarbital in wild type and humanized constitutive androstane receptor (CAR)/pregnane X receptor (PXR) mice and in cultured mouse, rat and human hepatocytes.

  2018cited by this paper
• Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells

  2018cited by this paper
• New insights into the role and mechanism of c‐Jun‐N‐terminal kinase signaling in the pathobiology of liver diseases

  2018cited by this paper
• Sensitivity of Simulated Hyporheic Exchange to River Bathymetry: The Steinlach River Test Site

  2018cited by this paper
• Role of bile acids in colon carcinogenesis

  2018cited by this paper
• Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK

  2018cited by this paper
• Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells

  2018cited by this paper
• The Role of Ferroptosis in Cancer Development and Treatment Response

  2018cited by this paper
• Mouse models for human intestinal microbiota research: a critical evaluation

  2017cited by this paper
• Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4−/− Mice

  2017cited by this paper
• Sodium cholate-enhanced polymeric micelle system for tumor-targeting delivery of paclitaxel

  2017cited by this paper
• Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System

  2017cited by this paper

• The antitumor mechanism of polysaccharides through regulating the microbiota-metabolism-immune axis and their clinical application strategies.

  2026cites this paper
• Isorhamnetin alleviates diet induced MASLD in mice by modulating gut microbiota and bile acid metabolism.

  2026cites this paper
• Multi-omics analysis reveals different cholesterol metabolism subtypes in colorectal cancer

  2025cites this paper
• Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment

  2025cites this paper